



Patent Docket P1810R1

1644  
P#S

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  Anan Chuntharapai et al.  Serial No.: 10/044,896  Filed: January 9, 2002  For: ANTI-INTERFERON-ALPHA ANTIBODIES	Group Art Unit: 1644  Examiner: Unknown
--	---

CERTIFICATE OF MAILING  
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on

January 10, 2003

*emilydutra*  
Emily Dutra

RECEIVED

JAN 17 2003

TECH CENTER 1600/2900

Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

37 CFR §1.97(b)

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); or
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR§1.491, or
- before the mailing of the first Office action on the merits; or
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

37 CFR §1.97(c)

- by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.

37 CFR §1.97(d)

- after the period specified in CFR §1.97(c), and is accompanied by the fee set forth in 37

CFR §1.17(p) and a statement as specified in 37 CFR §1.97(e), as checked below.

[If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.]

- 37 CFR §1.97(e)** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- 37 CFR §1.704(d)** Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified).

A copy of the items on PTO-1449 is supplied herewith. A copy of the PCT Search Report is also enclosed.

Those patent(s) or publication(s) which are marked with an asterisk (\*) in the attached PTO-1449 form are not supplied because they were previously cited by or submitted to the Office in a prior application Serial No. , filed and relied upon in this application for an earlier filing date under 35 USC §120.

BLAST results enclosed:

The undersigned also wishes to bring to the attention of the Examiner BLAST results of computerized alignments of the against sequences contained in the nucleotide and protein databases. The BLAST results are provided in paper form and are identified as reference "BLAST Results A-1- A-0" (nucleotide) and "BLAST Results B-1 - B-0" (protein) on the PTO Form 1449. Applicant requests that these references also be considered and that the Form 1449 be initialed to indicate the Examiner's consideration of the references.

A concise explanation of relevance of the items listed on PTO-1449 is:

- not given
- given for each listed item

Serial No.: 10/044,896  
Filed: January 9, 2002

Page 3

- given for only non-English language listed item(s) [Required]
- in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

GENENTECH, INC.

By:

  
Paul Naik, Ph.D.  
Reg. No. 49,075  
Telephone No. (650) 225-5530

Date: January 9, 2003



09157

PATENT TRADEMARK OFFICE

FORM PTO-1449 <b>LIST OF DISCLOSURES CITED BY APPLICANT</b> (Use several sheets if necessary)		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1810R1	Serial No. 10/044,896
				Applicant Chuntharapai et al.	
				Filing Date 09 Jan 2002	Group 1644

**U.S. PATENT DOCUMENTS**

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
1		4,885,166	05.12.89	Meyer et al.			
2		4,902,618	20.02.90	Berg			
3		6,180,370	30.01.01	Queen et al.			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
4		WO 96/34096	31.10.96	PCT				

**OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)**

5	Anonymous, "Human Interferon Alpha Subtypes, URL: <a href="http://www.researchd.com/cytokines/ifnasubt.htm">http://www.researchd.com/cytokines/ifnasubt.htm</a> " <u>Diagnostic Research, Inc.</u> (retrieved on Nov 25, 2002)
6	Jones et al., "Endocrine-Mediated Mechanisms of Fatigue During Treatment with Interferon-Alpha." <u>Seminars in Oncology</u> (Suppl. 1, ABSTRACT ONLY) 25(1):54-63 (Feb 1998)
7	Little et al., "Of Mice and Men: Hybridoma and Recombinant Antibodies." <u>Immunology Today</u> 21(8):364-370 (Aug 2000)
8	Okanoue Takeshi et al., "Side Effects of High-Dose Interferon Therapy for Chronic Hepatitis C." <u>J. Hepatology</u> (ABSTRACT ONLY) 25(3):283-291 (1996)
9	Seifarth et al., "Augmented Immune Response to Islet Cell Antigens and Development of Diabetes Mellitus Under Treatment with Interferon-Alpha in Chronic Hepatitis C." <u>Zeitschrift Fuer Gastroenterologie</u> (ABSTRACT ONLY) 37(3):235-239 (Mar 1999)

**RECEIVED**

JAN 17 2003

TECH CENTER 1600/2900

Examiner

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.